ADmit Therapeutics, S.L. is a company focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Our technology represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.